Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients
Introduction Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS). Methods We retrospectively analyzed the available bone mar...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2019-09, Vol.103 (3), p.208-214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 3 |
| container_start_page | 208 |
| container_title | European journal of haematology |
| container_volume | 103 |
| creator | Santaliestra, Marta Garrido, Ana Carricondo, Maite Bussaglia, Elena Pratcorona, Marta Blanco, Maria L. Gich, Ignasi Hoyos, Montserrat Esquirol, Albert García‐Cadenas, Irene Brunet, Salut Martino, Rodrigo Sierra, Jorge Nomdedéu, Josep F. |
| description | Introduction
Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS).
Methods
We retrospectively analyzed the available bone marrow (BM) samples from 115 patients with myeloid neoplasms obtained before and during treatment with 5‐azacytidine. A threshold of 100 copies in BM was used to define risk groups: group 1: patients with WT1 levels always below |
| doi_str_mv | 10.1111/ejh.13275 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2243492616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2277307814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-58fd7bc26c1d35606f5ac3a047db63e8bd37ad6742122786f3705f398ebffe13</originalsourceid><addsrcrecordid>eNp1kctK7TAUhoMc0e1l4AscAmeig2oubdI6U_GK4GSDw5I2K8ds2qYm3W62IPgIPqNPYrTqQDCTDP4vH1nrR2iHkn0azwHM7vYpZzJbQRMqCEmIIMUfNCEFYUmapnQdbYQwI4Swgso1tM4pozTPyQQ9HbsOcKu8dwt8O6W4gQdoArYd7tVgoRsCXtjhDrdLaJzVuAPXNyq0AQ8e1AB6jLPX5xf1qOrlYLXt4BBf6vjWGltHi-uwM9hD6F0X0__f6i20alQTYPvz3kTTs9PpyUVyfXN-eXJ0ndQ841mS5UbLqmaipppnggiTqZorkkpdCQ55pblUWsiUUcZkLgyXJDO8yKEyBijfRLujtvfufg5hKFsbamgaFaeZh5KxlKcFE1RE9N8PdObmvoufi5SUnMicppHaG6nauxA8mLL3Ni5xWVJSvldSxkrKj0oi-_fTOK9a0N_kVwcROBiBhW1g-bupPL26GJVv2-uXKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2277307814</pqid></control><display><type>article</type><title>Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Santaliestra, Marta ; Garrido, Ana ; Carricondo, Maite ; Bussaglia, Elena ; Pratcorona, Marta ; Blanco, Maria L. ; Gich, Ignasi ; Hoyos, Montserrat ; Esquirol, Albert ; García‐Cadenas, Irene ; Brunet, Salut ; Martino, Rodrigo ; Sierra, Jorge ; Nomdedéu, Josep F.</creator><creatorcontrib>Santaliestra, Marta ; Garrido, Ana ; Carricondo, Maite ; Bussaglia, Elena ; Pratcorona, Marta ; Blanco, Maria L. ; Gich, Ignasi ; Hoyos, Montserrat ; Esquirol, Albert ; García‐Cadenas, Irene ; Brunet, Salut ; Martino, Rodrigo ; Sierra, Jorge ; Nomdedéu, Josep F.</creatorcontrib><description>Introduction
Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS).
Methods
We retrospectively analyzed the available bone marrow (BM) samples from 115 patients with myeloid neoplasms obtained before and during treatment with 5‐azacytidine. A threshold of 100 copies in BM was used to define risk groups: group 1: patients with WT1 levels always below < 100 copies; group 2: cases with initial WT1 levels greater than 100 copies but with a conversion to sustained levels below 100; and group 3: cases with follow‐up WT1 levels greater than 100.
Results
Twenty patients were included in group 1, 17 in group 2, and 78 in group 3. Survival analysis showed statistically significant differences in terms of OS between groups (p: 0.016). Patients in group 2 showed the best 5‐year overall survival (OS). In multivariate analysis, only the cytogenetic risk category and receiving an allogeneic hematopoietic stem cell transplantation (HCT) independently predicted the survival.
Conclusions
Further studies are needed to assess whether BM WT1 levels could be useful to predict the survival of patients with myeloid neoplasms treated with 5‐azacytidine.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.13275</identifier><identifier>PMID: 31211880</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acute myeloid leukemia ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - pharmacology ; Antimetabolites, Antineoplastic - therapeutic use ; Azacitidine - pharmacology ; Azacitidine - therapeutic use ; Azacytidine ; Bone marrow ; Bone Marrow Cells - metabolism ; Combined Modality Therapy ; Cytogenetics ; demethylating agents ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Male ; Middle Aged ; molecular methods ; MRD ; mRNA ; Multivariate analysis ; Myelodysplastic syndrome ; Myelodysplastic Syndromes - drug therapy ; Myelodysplastic Syndromes - genetics ; Myeloid leukemia ; myeloid neoplasms ; Myeloproliferative Disorders - drug therapy ; Myeloproliferative Disorders - genetics ; Myeloproliferative Disorders - metabolism ; Myeloproliferative Disorders - pathology ; Risk groups ; Statistical analysis ; Stem cell transplantation ; Survival analysis ; Transplantation, Homologous ; Treatment Outcome ; Tumors ; WT1 ; WT1 Proteins - genetics ; WT1 Proteins - metabolism</subject><ispartof>European journal of haematology, 2019-09, Vol.103 (3), p.208-214</ispartof><rights>2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-58fd7bc26c1d35606f5ac3a047db63e8bd37ad6742122786f3705f398ebffe13</citedby><cites>FETCH-LOGICAL-c3535-58fd7bc26c1d35606f5ac3a047db63e8bd37ad6742122786f3705f398ebffe13</cites><orcidid>0000-0003-3399-346X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.13275$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.13275$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31211880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Santaliestra, Marta</creatorcontrib><creatorcontrib>Garrido, Ana</creatorcontrib><creatorcontrib>Carricondo, Maite</creatorcontrib><creatorcontrib>Bussaglia, Elena</creatorcontrib><creatorcontrib>Pratcorona, Marta</creatorcontrib><creatorcontrib>Blanco, Maria L.</creatorcontrib><creatorcontrib>Gich, Ignasi</creatorcontrib><creatorcontrib>Hoyos, Montserrat</creatorcontrib><creatorcontrib>Esquirol, Albert</creatorcontrib><creatorcontrib>García‐Cadenas, Irene</creatorcontrib><creatorcontrib>Brunet, Salut</creatorcontrib><creatorcontrib>Martino, Rodrigo</creatorcontrib><creatorcontrib>Sierra, Jorge</creatorcontrib><creatorcontrib>Nomdedéu, Josep F.</creatorcontrib><title>Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Introduction
Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS).
Methods
We retrospectively analyzed the available bone marrow (BM) samples from 115 patients with myeloid neoplasms obtained before and during treatment with 5‐azacytidine. A threshold of 100 copies in BM was used to define risk groups: group 1: patients with WT1 levels always below < 100 copies; group 2: cases with initial WT1 levels greater than 100 copies but with a conversion to sustained levels below 100; and group 3: cases with follow‐up WT1 levels greater than 100.
Results
Twenty patients were included in group 1, 17 in group 2, and 78 in group 3. Survival analysis showed statistically significant differences in terms of OS between groups (p: 0.016). Patients in group 2 showed the best 5‐year overall survival (OS). In multivariate analysis, only the cytogenetic risk category and receiving an allogeneic hematopoietic stem cell transplantation (HCT) independently predicted the survival.
Conclusions
Further studies are needed to assess whether BM WT1 levels could be useful to predict the survival of patients with myeloid neoplasms treated with 5‐azacytidine.</description><subject>Acute myeloid leukemia</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - pharmacology</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Azacitidine - pharmacology</subject><subject>Azacitidine - therapeutic use</subject><subject>Azacytidine</subject><subject>Bone marrow</subject><subject>Bone Marrow Cells - metabolism</subject><subject>Combined Modality Therapy</subject><subject>Cytogenetics</subject><subject>demethylating agents</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>molecular methods</subject><subject>MRD</subject><subject>mRNA</subject><subject>Multivariate analysis</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Myelodysplastic Syndromes - genetics</subject><subject>Myeloid leukemia</subject><subject>myeloid neoplasms</subject><subject>Myeloproliferative Disorders - drug therapy</subject><subject>Myeloproliferative Disorders - genetics</subject><subject>Myeloproliferative Disorders - metabolism</subject><subject>Myeloproliferative Disorders - pathology</subject><subject>Risk groups</subject><subject>Statistical analysis</subject><subject>Stem cell transplantation</subject><subject>Survival analysis</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>WT1</subject><subject>WT1 Proteins - genetics</subject><subject>WT1 Proteins - metabolism</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctK7TAUhoMc0e1l4AscAmeig2oubdI6U_GK4GSDw5I2K8ds2qYm3W62IPgIPqNPYrTqQDCTDP4vH1nrR2iHkn0azwHM7vYpZzJbQRMqCEmIIMUfNCEFYUmapnQdbYQwI4Swgso1tM4pozTPyQQ9HbsOcKu8dwt8O6W4gQdoArYd7tVgoRsCXtjhDrdLaJzVuAPXNyq0AQ8e1AB6jLPX5xf1qOrlYLXt4BBf6vjWGltHi-uwM9hD6F0X0__f6i20alQTYPvz3kTTs9PpyUVyfXN-eXJ0ndQ841mS5UbLqmaipppnggiTqZorkkpdCQ55pblUWsiUUcZkLgyXJDO8yKEyBijfRLujtvfufg5hKFsbamgaFaeZh5KxlKcFE1RE9N8PdObmvoufi5SUnMicppHaG6nauxA8mLL3Ni5xWVJSvldSxkrKj0oi-_fTOK9a0N_kVwcROBiBhW1g-bupPL26GJVv2-uXKA</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Santaliestra, Marta</creator><creator>Garrido, Ana</creator><creator>Carricondo, Maite</creator><creator>Bussaglia, Elena</creator><creator>Pratcorona, Marta</creator><creator>Blanco, Maria L.</creator><creator>Gich, Ignasi</creator><creator>Hoyos, Montserrat</creator><creator>Esquirol, Albert</creator><creator>García‐Cadenas, Irene</creator><creator>Brunet, Salut</creator><creator>Martino, Rodrigo</creator><creator>Sierra, Jorge</creator><creator>Nomdedéu, Josep F.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3399-346X</orcidid></search><sort><creationdate>201909</creationdate><title>Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients</title><author>Santaliestra, Marta ; Garrido, Ana ; Carricondo, Maite ; Bussaglia, Elena ; Pratcorona, Marta ; Blanco, Maria L. ; Gich, Ignasi ; Hoyos, Montserrat ; Esquirol, Albert ; García‐Cadenas, Irene ; Brunet, Salut ; Martino, Rodrigo ; Sierra, Jorge ; Nomdedéu, Josep F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-58fd7bc26c1d35606f5ac3a047db63e8bd37ad6742122786f3705f398ebffe13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute myeloid leukemia</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - pharmacology</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Azacitidine - pharmacology</topic><topic>Azacitidine - therapeutic use</topic><topic>Azacytidine</topic><topic>Bone marrow</topic><topic>Bone Marrow Cells - metabolism</topic><topic>Combined Modality Therapy</topic><topic>Cytogenetics</topic><topic>demethylating agents</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>molecular methods</topic><topic>MRD</topic><topic>mRNA</topic><topic>Multivariate analysis</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Myelodysplastic Syndromes - genetics</topic><topic>Myeloid leukemia</topic><topic>myeloid neoplasms</topic><topic>Myeloproliferative Disorders - drug therapy</topic><topic>Myeloproliferative Disorders - genetics</topic><topic>Myeloproliferative Disorders - metabolism</topic><topic>Myeloproliferative Disorders - pathology</topic><topic>Risk groups</topic><topic>Statistical analysis</topic><topic>Stem cell transplantation</topic><topic>Survival analysis</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>WT1</topic><topic>WT1 Proteins - genetics</topic><topic>WT1 Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santaliestra, Marta</creatorcontrib><creatorcontrib>Garrido, Ana</creatorcontrib><creatorcontrib>Carricondo, Maite</creatorcontrib><creatorcontrib>Bussaglia, Elena</creatorcontrib><creatorcontrib>Pratcorona, Marta</creatorcontrib><creatorcontrib>Blanco, Maria L.</creatorcontrib><creatorcontrib>Gich, Ignasi</creatorcontrib><creatorcontrib>Hoyos, Montserrat</creatorcontrib><creatorcontrib>Esquirol, Albert</creatorcontrib><creatorcontrib>García‐Cadenas, Irene</creatorcontrib><creatorcontrib>Brunet, Salut</creatorcontrib><creatorcontrib>Martino, Rodrigo</creatorcontrib><creatorcontrib>Sierra, Jorge</creatorcontrib><creatorcontrib>Nomdedéu, Josep F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santaliestra, Marta</au><au>Garrido, Ana</au><au>Carricondo, Maite</au><au>Bussaglia, Elena</au><au>Pratcorona, Marta</au><au>Blanco, Maria L.</au><au>Gich, Ignasi</au><au>Hoyos, Montserrat</au><au>Esquirol, Albert</au><au>García‐Cadenas, Irene</au><au>Brunet, Salut</au><au>Martino, Rodrigo</au><au>Sierra, Jorge</au><au>Nomdedéu, Josep F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2019-09</date><risdate>2019</risdate><volume>103</volume><issue>3</issue><spage>208</spage><epage>214</epage><pages>208-214</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Introduction
Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS).
Methods
We retrospectively analyzed the available bone marrow (BM) samples from 115 patients with myeloid neoplasms obtained before and during treatment with 5‐azacytidine. A threshold of 100 copies in BM was used to define risk groups: group 1: patients with WT1 levels always below < 100 copies; group 2: cases with initial WT1 levels greater than 100 copies but with a conversion to sustained levels below 100; and group 3: cases with follow‐up WT1 levels greater than 100.
Results
Twenty patients were included in group 1, 17 in group 2, and 78 in group 3. Survival analysis showed statistically significant differences in terms of OS between groups (p: 0.016). Patients in group 2 showed the best 5‐year overall survival (OS). In multivariate analysis, only the cytogenetic risk category and receiving an allogeneic hematopoietic stem cell transplantation (HCT) independently predicted the survival.
Conclusions
Further studies are needed to assess whether BM WT1 levels could be useful to predict the survival of patients with myeloid neoplasms treated with 5‐azacytidine.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31211880</pmid><doi>10.1111/ejh.13275</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3399-346X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2019-09, Vol.103 (3), p.208-214 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2243492616 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acute myeloid leukemia Aged Aged, 80 and over Antimetabolites, Antineoplastic - pharmacology Antimetabolites, Antineoplastic - therapeutic use Azacitidine - pharmacology Azacitidine - therapeutic use Azacytidine Bone marrow Bone Marrow Cells - metabolism Combined Modality Therapy Cytogenetics demethylating agents Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Male Middle Aged molecular methods MRD mRNA Multivariate analysis Myelodysplastic syndrome Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics Myeloid leukemia myeloid neoplasms Myeloproliferative Disorders - drug therapy Myeloproliferative Disorders - genetics Myeloproliferative Disorders - metabolism Myeloproliferative Disorders - pathology Risk groups Statistical analysis Stem cell transplantation Survival analysis Transplantation, Homologous Treatment Outcome Tumors WT1 WT1 Proteins - genetics WT1 Proteins - metabolism |
| title | Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A13%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20marrow%20WT1%20levels%20in%20patients%20with%20myeloid%20neoplasms%20treated%20with%205%E2%80%90azacytidine:%20Identification%20of%20responding%20patients&rft.jtitle=European%20journal%20of%20haematology&rft.au=Santaliestra,%20Marta&rft.date=2019-09&rft.volume=103&rft.issue=3&rft.spage=208&rft.epage=214&rft.pages=208-214&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.13275&rft_dat=%3Cproquest_cross%3E2277307814%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2277307814&rft_id=info:pmid/31211880&rfr_iscdi=true |